# US 2025/0170309 A1 · Degradable particles comprising high levels of rapamycin

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0170309 A1
- Document ID: US20250170309A1
- Status: Published application
- Kind: A1
- Application number: 18/834,392
- Filed: 2023-01-27
- Published: 2025-05-29
- Earliest claimed: 2022-02-01
- Assignees: Dsm IP Assets B.V.
- Applicants: DSM IP Assets B.V.
- Inventors: Matilde PUTTI; Megan HOEN; Gueorgui MIHOV; Jérôme George Jozeph Louis LEBOUILLE
- Web page: https://patentgrep.com/patent/US20250170309A1

## CPC

- A61L 29/085: {Macromolecular materials}
- A61L 31/10: Macromolecular materials
- A61K 9/0092: {Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes}
- A61K 9/5031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)}
- A61K 31/436: the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A61L 29/148: {Materials at least partially resorbable by the body}
- A61L 29/16: Biologically active materials, e.g. therapeutic substances {(A61L29/048 takes precedence)}
- A61L 31/148: {Materials at least partially resorbable by the body}
- A61L 31/16: Biologically active materials, e.g. therapeutic substances {(A61L31/047 takes precedence)}
- A61L 2300/416: Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
- A61L 2300/622: Microcapsules
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Disclosed are drug delivery devices, coatings, and microparticles that achieve sufficiently small particle sizes with high loading of Rapamycin. In an embodiment, a balloon comprises a coating on its exterior surface, the coating comprising microparticles having a Dv90 particle size of from 1 to 11 μm, as measured with static laser scattering, the microparticles comprising from 35 to 50 wt % of rapamycin, based on the total weight of the microparticles, and a random copolymer according to Formula (I).

## Claims

### Claim 1

A balloon comprising a coating on its exterior surface, the coating comprising microparticles having a Dv90 particle size of from 1 to 11 μm, as measured with static laser scattering, the microparticles comprising from 35 to 50 wt % of rapamycin, based on the total weight of the microparticles, and a random copolymer according to Formula I:
wherein
m, p, q, and x represent the equivalents of the corresponding units in the random copolymer and m+p+q+x=1;
m is from 0 to 0.75, p is from 0 to 0.75, m+p is from is from 0.5 to 0.9, q is from 0.05 to 0.25, x is from 0.01 to 0.25, and q:x is from 9:1 to 1:4;
n is from 5 to 300;
R1 is C2-C20 alkylene;
R3 and R4 are hydrogen, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C6-C10)aryl, —CH2SH, —(CH2)2S(CH3), —CH2OH, —CH(OH)CH3, —(CH2)4NH3+, —(CH2)3NHC(═NH2+)NH2, —CH2COOH, —CH2—CO—NH2, —CH2CH2—CO—NH2, —CH2CH2COOH, CH3—CH2—CH(CH3)—, (CH3)2CH—CH2—, H2N—(CH2)4—, Ph-CH2—, CH═C—CH2—, (CH3)2CH—, Ph-NH—,
wherein R3 and R4 may be the same or different;
R6 is according to Formula II or Formula III;
R7 is (C6-C10)aryl(C1-C6)alkylene; and
R8 is C3-C8 alkylene.

### Claim 2 (depends on 1)

The balloon of claim 1, wherein x is from 0.02 to 0.15.

### Claim 3 (depends on 1)

The balloon of claim 1, wherein m is from 0.10 to 0.75 and p is from 0.10 to 0.75.

### Claim 4 (depends on 1)

The balloon of claim 1, wherein m is from 0.25 to 0.35, p is from 0.40 to 0.50, m+p is from 0.70 to 0.80, q is from 0.15 to 0.25, and x is from 0.03 to 0.10.

### Claim 5 (depends on 1)

The balloon of claim 1, wherein the ratio of q to x is from 5:1 to 1:1.

### Claim 6 (depends on 1)

The balloon of claim 1, wherein the ratio of q to x is from 4:1 to 2:1.

### Claim 7 (depends on 1)

The balloon of claim 1, wherein R3 and R4 are hydrogen, (C1-C6)alkyl, CH3—CH2—CH(CH3)—, (CH3)2CH—CH2—, Ph-CH2—, or (CH3)2CH—.

### Claim 8 (depends on 1)

The balloon of claim 1, wherein R6 is according to Formula II.

### Claim 9 (depends on 1)

The balloon of claim 1, wherein R7 is C6aryl-CH2—.

### Claim 10 (depends on 1)

The balloon of claim 1, wherein the microparticles comprise from 35 to 45 wt % of rapamycin.

### Claim 11

A method of forming microparticles comprising the steps of:
a. forming an oil phase comprising from 1 to 2.5 wt % Rapamycin, 1.5 to 2.5 wt % of a random copolymer according to Formula I, and from 95 to 97.5 wt % of chloroform or dichloromethane,
b. forming a continuous phase comprising water and from 0 to 1 wt % of an emulsifier, and
c. adding the oil phase to continuous phase under high shear,
wherein the random copolymer according to Formula I is as follows:
wherein
m, p, q, and x represent the equivalents of the corresponding units in the random copolymer and m+p+q+x=1;
m is from 0 to 0.75, p is from 0 to 0.75, m+p is from is from 0.5 to 0.9, q is from 0.05 to 0.25, x is from 0.03 to 0.25, and q:x is from 9:1 to 1:4;
n is from 5 to 300;
R1 is C2-C20 alkylene;
R3 and R4 are hydrogen, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C6-C10)aryl, —CH2SH, —(CH2)2S(CH3), —CH2OH, —CH(OH)CH3, —(CH2)4NH3+, —(CH2)3NHC(═NH2+)NH2, —CH2COOH, —CH2—CO—NH2, —CH2CH2—CO—NH2, —CH2CH2COOH, CH3—CH2—CH(CH3)—, (CH3)2CH—CH2—, H2N—(CH2)4—, Ph-CH2—, CH═C—CH2—, (CH3)2CH—, Ph-NH—,
wherein R3 and R4 may be the same or different;
R6 is according to Formula II or Formula III;
R7 is (C6-C10)aryl(C1-C6)alkylene; and
R8 is C3-C8 alkylene.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the oil phase further comprises an antioxidant.

### Claim 13 (depends on 12)

The method according to claim 12, wherein the antioxidant comprises butylated hydroxytoluene.

### Claim 14 (depends on 11)

The method according to claim 11, wherein the emulsifier comprises a polyvinyl alcohol.

### Claim 15 (depends on 11)

The method according to claim 11, wherein the oil-phase comprises from 1.25 to 2.1 wt % of Rapamycin, from 1.5 to 2.5 wt % of the random copolymer according to Formula I, and from 95.5 to 97.2 wt % of chloroform or dichloromethane.

### Claim 16 (depends on 11)

The method according to claim 11, wherein the oil-phase comprises from 1.25 to 2.1 wt % of Rapamycin, from 1.9 to 2.07 wt % of the random copolymer according to Formula I, and from 95.5 to 97.0 wt % of chloroform or dichloromethane.

### Claim 17 (depends on 1)

A dispersion of microparticles in water formed by the method of claim 1.

### Claim 18 (depends on 17)

The dispersion of claim 17, wherein the microparticles have a Dv90 particle size of from 1 to 11 μm, as measured with static laser scattering, and comprise from 35 to 45 wt % of rapamycin.

### Claim 19

A plurality of microparticles having a Dv90 particle size of from 1 to 11 μm, as measured with static laser scattering, the microparticles consisting of from 35 to 50 wt % of rapamycin, based on the total weight of the microparticles, and a random copolymer according to Formula I:
wherein
m, p, q, and x represent the equivalents of the corresponding units in the random copolymer and m+p+q+x=1;
m is from 0 to 0.75, p is from 0 to 0.75, m+p is from is from 0.5 to 0.9, q is from 0.05 to 0.25, x is from 0.01 to 0.25, and q:x is from 9:1 to 1:4;
n is from 5 to 300;
R1 is C2-C20 alkylene;
R3 and R4 are hydrogen, (C1-C6)alkyl, (C2-C6)alkenyl, (C2-C6)alkynyl, (C6-C10)aryl, —CH2SH, —(CH2)2S(CH3), —CH2OH, —CH(OH)CH3, —(CH2)4NH3+, —(CH2)3NHC(═NH2+)NH2, —CH2COOH, —CH2—CO—NH2, —CH2CH2—CO—NH2, —CH2CH2COOH, CH3—CH2—CH(CH3)—, (CH3)2CH—CH2—, H2N—(CH2)4—, Ph-CH2—, CH═C—CH2—, (CH3)2CH—, Ph-NH—,
wherein R3 and R4 may be the same or different;
R6 is according to Formula II or Formula III;
R7 is (C6-C10)aryl(C1-C6)alkylene; and
R8 is C3-C8 alkylene.

### Claim 20 (depends on 19)

A coating comprising the plurality of microparticles according to claim 19.

### Claim 21 (depends on 1)

A method of treating a human or animal patient comprising the steps of:
a. providing the balloon in accordance with claim 1;
b. positioning the balloon in a blood vessel of a patient;
c. inflating the balloon and thereby transferring a quantity of the microparticles to a wall of the blood vessel; and
d. deflating the balloon and removing the coated balloon from the blood vessel of the patient.

### Claim 22 (depends on 1)

Use of the balloon according to claim 1 for treating an arterial disease.

### Claim 23 (depends on 1)

The balloon according to claim 1 for use in treating an arterial disease of a patient.
